Human apolipoprotein E has three isoforms: APOE2, APOE3 and APOE4 1 . APOE4 is a major genetic risk factor for Alzheimer's disease 2,3 and is associated with Down's syndrome dementia and poor neurological outcome after traumatic brain injury and haemorrhage 3 . Neurovascular dysfunction is present in normal APOE4 carriers [4] [5] [6] and individuals with APOE4-associated disorders 3, [7] [8] [9] [10] . In mice, lack of Apoe leads to blood-brain barrier (BBB) breakdown 11, 12 , whereas APOE4 increases BBB susceptibility to injury 13 . How APOE genotype affects brain microcirculation remains elusive. Using different APOE transgenic mice, including mice with ablation and/or inhibition of cyclophilin A (CypA), here we show that expression of APOE4 and lack of murine Apoe, but not APOE2 and APOE3, leads to BBB breakdown by activating a proinflammatory CypA-nuclear factorkB-matrix-metalloproteinase-9 pathway in pericytes. This, in turn, leads to neuronal uptake of multiple blood-derived neurotoxic proteins, and microvascular and cerebral blood flow reductions. We show that the vascular defects in Apoe-deficient and APOE4-expressing mice precede neuronal dysfunction and can initiate neurodegenerative changes. Astrocyte-secreted APOE3, but not APOE4, suppressed the CypA-nuclear factor-kB-matrixmetalloproteinase-9 pathway in pericytes through a lipoprotein receptor. Our data suggest that CypA is a key target for treating APOE4-mediated neurovascular injury and the resulting neuronal dysfunction and degeneration.
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Astrocytes are a major source of APOE in the brain 2 . Importantly, astrocyte-secreted molecules transduce signals to brain microvessels acting on pericytes 7, 14, 15 . To understand the effects of APOE on brain microcirculation we studied mice with targeted replacement of murine Apoe with each human APOE isoform (TR-APOE) 16 , mice lacking murine Apoe (Apoe 2/2 ), mice expressing each human APOE isoform under control of the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter on an Apoe-null background, and Apoe 2/2 and APOE4 transgenic mice with ablation and/or pharmacological inhibition of CypA (see Supplementary Information). In search of molecules that could mediate BBB dysfunction in Apoe 2/2 and APOE4 mice, we focused on the proinflammatory cytokine CypA, previously demonstrated to have deleterious effects on the vascular system in Apoe 2/2 mice with aortic aneurysms and atherosclerosis 17, 18 . Using multiphoton microscopy of tetramethylrhodamineconjugated dextran (TMR-dextran) 14 , we show an intact BBB in TR-APOE2 and TR-APOE3 mice and a leaky BBB in TR-APOE4 and Apoe 2/2 mice ( Fig. 1a and Supplementary Fig. 1a, b) , suggesting that APOE2, APOE3 and murine Apoe effectively maintain the BBB, whereas APOE4 promotes BBB disruption. These findings have been replicated in mice expressing each human APOE isoform under control of the GFAP promoter (not shown). Notably, genetic ablation of CypA (encoded by Ppia) eliminated BBB damage in Apoe 2/2 Ppia 2/2 mice ( Fig. 1a and Supplementary Fig. 1a, b ).
Compared to littermate controls, TR-or GFAP-APOE2 and -APOE3 mice, Apoe 2/2 and APOE4 mice had five-to sixfold higher CypA levels in cerebral microvessels (Fig. 1b and Supplementary Fig. 1c, d ), mainly because of an increased CypA expression in pericytes ( Fig. 1c and Supplementary Fig. 1e ). CypA levels in microvessel-depleted brain were not affected by APOE ( Supplementary  Fig. 1f ). These data suggest that APOE2, APOE3 and murine Apoe, but not APOE4, effectively maintain physiological CypA levels in brain microvessels by controlling CypA expression in pericytes. To determine whether BBB disruption in APOE4 mice can be corrected with cyclosporine A, a drug that binds intracellular CypA and inhibits its effects 19 , we treated TR-APOE4 and GFAP-APOE4 mice with a low dose of cyclosporine A previously shown not to cause systemic or central nervous system toxicity. Cyclosporine A accumulates in brain microvessels, but does not cross the BBB 20 . In APOE4 mice cyclosporine A eliminated BBB disruption ( Fig. 1a and Supplementary Fig. 1a, b ) and neuronal accumulation of systemically administered cadaverine 15 ( Supplementary Fig. 1g ), indicating that BBB changes are reversible and CypA can be therapeutically targeted to correct APOE4-induced BBB breakdown.
To understand better the pathological implications of BBB breakdown, we studied leakage of endogenous blood-derived proteins in the brain. As shown in the hippocampus, 18-month-old GFAP-APOE3 and control mice had negligible extravascular accumulation of serum IgG in contrast to GFAP-APOE4 and Apoe 2/2 mice ( Supplementary  Fig. 2a, b) . Ppia genetic deletion eliminated IgG extravascular deposits ( Supplementary Fig. 2a, b ) and neuronal accumulation in Apoe 2/2 and APOE4 mice (Fig. 1d) . Cyclosporine A diminished IgG leakage by ,80% in TR-APOE4 or GFAP-APOE4 mice ( Supplementary Fig. 2c ) and inhibited neuronal accumulation of blood-derived thrombin and fibrin (Fig. 1e) , consistent with restoration of the BBB. APOE4 mice had numerous brain perivascular fibrin and haemosiderin foci (Supplementary Fig. 2d-f ) and elevated thrombin levels that were normalized with cyclosporine A (Supplementary Fig. 2g, h ). Thrombin is neurotoxic 21 , fibrin accelerates neurovascular damage 22 and haemosiderin generates reactive oxygen species 23 , thus implicating multiple potential BBB-derived sources of injury.
To elucidate the molecular mechanisms underlying CypA-mediated BBB breakdown we studied matrix metalloproteinases (MMP)2 and MMP9 (gelatinases), which are activated by CypA in the vessel wall in a mouse model of aortic aneurism 17 . Gelatinases disrupt the BBB by degrading the capillary basement membrane and tight-junction proteins 7, 24 . Multiphoton microscopy of DQ-gelatin 25 revealed an increase in cerebrovascular gelatinase activity in Apoe 2/2 Ppia 1/1 and TR-APOE4 mice compared with controls, TR-APOE2 and TR-APOE3 mice (Fig. 2a, b) . Gelatin zymography of brain tissue demonstrated an increase in pro-MMP9 and activated MMP9, but not MMP2, in Apoe 2/2 and TR-APOE4 mice (Fig. 2c ), which correlated with the appearance of MMP9-positive pericytes ( Fig. 2d and Supplementary  Fig. 3a, b ).
To establish causality and demonstrate that increased MMP9 activity does not only correlate with, but is required for, BBB breakdown in Apoe 2/2 and TR-APOE4 mice, we studied the effects of pharmacological inhibition of MMP9 in vivo with 2-[[(4-phenoxyphenyl) sulfonyl]methyl]-Thiirane (SB-3CT), an MMP9 inhibitor, and of MMP9 and MMP2 silencing by short interfering (si)RNA administration into the hippocampus, as reported 26 . SB-3CT eliminated MMP9 gelatinase activity (Fig. 2b, c ) and reversed the leaky BBB phenotype ( Supplementary Fig. 4a ) in both mouse lines. Similarly, MMP9, but not MMP2, silencing reversed the BBB phenotype in TR-APOE4 mice ( Supplementary Fig. 4b ). Similar results were obtained with siMmp9 treatment in Apoe 2/2 mice (not shown). Consistent with MMP9 activation, several MMP9 substrates including collagen IV and tight-junction proteins ZO-1 (also known as Tjp1), occludin and claudin 5, which are required for normal BBB integrity 7,24, were reduced in brain microvessels in young Apoe 2/2 and APOE4 A p o e -/- LETTER RESEARCH mice, indicating BBB breakdown (Fig. 2e and Supplementary Fig. 3c-f) . SB-3CT (Supplementary Fig. 4c ) and siMMP-9, but not siMMP-2 or control siRNA, normalized the levels of tight-junction and basementmembrane proteins in APOE4 (Supplementary Fig. 4b ) and Apoe 2/2 mice (not shown). These data explain how MMP9 inhibition permits reversal of BBB disruption in Apoe 2/2 and APOE4 mice at a molecular level. Notably, genetic deletion of Ppia or cyclosporine A substantially inhibited gelatinase/MMP9 activity (Fig. 2a-c) and TR-APOE4 mice (Fig. 2e and Supplementary Figs 3c-f, 4c) . Nuclear-factor-kB (NF-kB) transcriptionally activates MMP9 in cerebral vessels, causing BBB breakdown 24 . Consistent with findings that CypA at pathophysiological levels activates NF-kB and the NFkB-MMP9 pathway 18, 24, 27 , we found NF-kB nuclear translocation in brain capillary pericytes in Apoe 2/2 and APOE4 mice ( Supplementary  Fig. 5a, b) . In both Apoe 2/2 and APOE4 mice, NF-kB nuclear translocation was inhibited by Ppia gene deletion and/or cyclosporine A ( Supplementary Fig. 5a, b) .
To establish the causality between NF-kB activation, increased gelatinase activity and BBB breakdown, we treated Apoe 2/2 and APOE4 mice with pyrrolidine dithiocarbamate (PDTC), an inhibitor of NF-kB nuclear translocation. In Apoe 2/2 and APOE4 mice, PDTC markedly reduced MMP9 activation (Fig. 2b, c and Supplementary  Fig. 3b ) and reversed the leaky BBB phenotype (Supplementary Fig. 4a ). Consistent with these data, NF-kB inhibition in the hippocampus by silencing Rela, which encodes the p65 subunit of NF-kB, inhibited MMP9 and reversed the BBB phenotype in APOE4 mice (Supplementary Fig. 4c) . Similar results were obtained by silencing Rela in Apoe 2/2 mice (not shown). Our findings therefore clearly establish that each of the molecules studied (that is, CypA, NF-kB and MMP9) have important and required roles in BBB disruption in Apoe 2/2 and APOE4 mice.
Consistent with reports that chronic BBB breakdown leads to microvascular reductions 7, 14, 22 , we found microvascular degeneration in APOE4 and Apoe 2/2 mice, including DNA fragmentation in pericytes and endothelial cells ( Supplementary Fig. 6a ), diminished pericyte coverage ( Supplementary Fig. 5b, c) and reductions in microvascular length ( Fig. 3a and Supplementary Fig. 6d ), which correlated with the degree of BBB breakdown ( Supplementary Fig. 6e ) and regional cerebral blood flow (CBF) reductions (Fig. 3b and Supplementary  Table 1) . Notably, Ppia deletion and cyclosporine A, SB-3CT or PDTC normalized microvascular reductions in Apoe 2/2 and APOE4 mice ( Fig. 3a and Supplementary Fig. 6c ). Ppia deletion also normalized CBF reductions in Apoe 2/2 mice (Fig. 3b) . Given that CypA expression and NF-kB and MMP9 activation are increased in pericytes in Apoe 2/2 and APOE4 mice, we next studied which low-density lipoprotein (LDL)/APOE receptor 1 in pericytes regulates CypA in response to astrocyte-derived APOE. After confirming the specificity of our siRNA reagents ( Supplementary Fig. 7) , we showed by quantifying the effects of siRNA inhibition ( Fig. 4a and Supplementary Fig. 8a-d) and by administering antibodies to block the function of specific LDL receptors ( Supplementary Fig. 8e-g ) that astrocyte-derived APOE3 and murine Apoe require low-density lipoprotein receptor-related protein 1 (LRP1) to maintain CypA synthesis within a physiological range. Adenoviral-mediated re-expression of a human LRP1 minigene rescued the ability of APOE3 to downregulate Ppia mRNA (Fig. 4a) and protein (Supplementary Fig. 8b ) in pericytes with siRNA-induced LRP1 knockdown. By imaging APOE/LRP1 proximity ligation in pericytes we demonstrated that APOE3 (Fig. 4b ) and murine Apoe (not shown) bind with high affinity to LRP1, whereas the APOE4-LRP1 interaction was barely detectable (Fig. 4b) . Together these data explain at the molecular level why APOE4 is unable to properly regulate physiologic CypA levels, which is consistent with previously reported statistically insignificant interactions of APOE4 with LRP1 in cerebral microvessels and at the BBB in vivo 28 .
Ppia silencing, cyclosporine A and astrocyte-derived APOE3, but not APOE4, inhibited NF-kB nuclear translocation in Apoe 2/2 pericytes ( Supplementary Fig. 9a ), as in vivo. By using siLrp1 silencing, cyclosporine A or PDTC, we showed that LRP1 is required for APOE3-mediated inhibition of NF-kB-dependent MMP9 activation and transcriptional suppression 24 ( Supplementary Fig. 9 ). APOE4 did not have an effect on MMP9 in pericytes, consistent with its barely detectable binding to LRP1 (Fig. 4b) . In vivo, LRP1 inhibition in APOE3 mice through siRNA administration in the hippocampus 26 reproduced vascular phenotypes seen in APOE4 mice, including elevated CypA and MMP9 levels and increased CypA and MMP9 expression in pericytes ( Fig. 4c and Supplementary Fig. 10a, b) , and BBB breakdown (Fig. 4d) . As expected, LRP1 inhibition in mice with Ppia genetic deletion did not influence MMP9 expression in pericytes ( Supplementary Fig. 10d ) or BBB integrity (Supplementary Fig. 10d ). Together, these data clearly implicate APOE3/LRP1-mediated CypA regulation in pericytes, conferring APOE3 isoform-specific protection of the BBB (Fig. 4e) .
Vascular defects in Apoe 2/2 and APOE4 mice were detectable at 2 weeks of age, including leakage of dextran (Fig. 5a ) and serum IgG ( Supplementary Fig. 11a ), and reductions in tight-junction and basement-membrane proteins, pericyte coverage, capillary length and regional CBF, which progressively increased with age ( Fig. 2e and Supplementary Figs 11b- , and neuronal and synaptic dysfunction in APOE4 mice 2 . Cortical activity determined in vivo by voltage-sensitive dye (VSD) imaging indicated normal time-lapse imaging profiles in 2-week-old Apoe 2/2 and APOE4 mice ( Fig. 5b and Supplementary  Fig. 13a, b) and normal neuritic density and levels of pre-synaptic and post-synaptic proteins ( Supplementary Fig. 14a-d) . At 4 months of age, however, Apoe 2/2 and APOE4 mice showed a lower amplitude 
RESEARCH LETTER
of the VSD signal, longer time-to-peak and a slower duration of the spreading of depolarization (Fig. 5c, d ), which was accompanied by age-dependent reductions in neuritic density and pre-synaptic and post-synaptic proteins ( Supplementary Fig. 14a-f) . These data indicate that Apoe 2/2 and APOE4 mice develop vascular defects before neuronal and synaptic changes occur. Cyclosporine A, PDTC and SB-3CT improved functional and structural neuronal changes in Apoe 2/2 and APOE4 mice (Fig. 5e and Supplementary Fig. 15 ), indicating that normalization of BBB integrity through inhibition of the CypA-NFkB-MMP9 pathway is required for neuronal and synaptic repair.
Understanding the contribution of APOE4 to the pathogenesis of Alzheimer's disease may be one of the most important avenues to a new therapy. Neurovascular dysfunction and BBB defects have been shown in Alzheimer's disease 7, 30 . The findings from this study indicating that abnormal vessels and pericytes can be involved provide an alternative way of thinking about Alzheimer's disease and neurological disorders affected by APOE4. Our findings demonstrate that APOE maintains cerebrovascular integrity necessary for normal neuronal function by regulating the CypA-NF-kB-MMP9 pathway in pericytes in an isoform-specific manner (Fig. 4e) . We also show that CypA is a key target for treating APOE4-mediated neurovascular defects and the resulting neuronal dysfunction.
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Animals. Apoe
2/2
, GFAP-APOE mice on murine Apoe-null background and Ppia 2/2 mice were acquired from Jackson Laboratories. TR-APOE mice were generated as previously described 16 . The Ppia 2/2 mice were crossed with the Apoe 2/2 and TR-APOE4 mice to generate the Apoe 2/2 Ppia 2/2 and TR-APOE4 Ppia 2/2 mice used in the present study, respectively. Mice were housed in plastic cages on a 12-hour light cycle with ad libitum access to water and a standard laboratory diet. All studies were performed in accordance with the University of Rochester Institutional Animal Care and Use Committee using LETTER RESEARCH
